Skip to main content

Advertisement

Table 2 Selected clinical studies on the treatment of stage I/II NK/T-cell lymphoma

From: The diagnosis and management of NK/T-cell lymphomas

Study (reference) No. Treatment ORR CR OS PFS
Retrospective [59] 253 RT (50 Gy) NR NR 5-year: 70% 5-year: 65%
Phase II [61, 65] 150 CCRT (50 Gy) + 2/3 DeVIC 89% 82% 5-year: 72% 5-year: 61%
Phase II [63] 30 CCRT (40 Gy) + VIPD 83% 80% 3-year: 86% 3-year: 85%
Phase II [64] 30 CCRT (40 Gy) + VIDL 90% 87% 5-year: 73% 5-year: 60%
Phase II [69, 70] 26 LVP + sandwiched RT (56 Gy) 89% 81% 5-year: 64% 5-year: 64%
Phase II [70, 71] 27 GELOX + sandwiched RT (56 Gy) 96% 74% 5-year: 85% 5-year: 74%
Phase II [73] 33 DICE-L + RT (45 Gy) 91% 100% 5-year: 89% 5-year: 82%
Retrospective [68] 29 SMILE + sandwiched RT (50 Gy) 90% 69% NR NR
  1. No. number of patients, ORR overall response rate, CR complete response rate, OS overall survival, PFS progression-free survival, NR not reported, RT radiotherapy, CCRT concurrent chemoradiotherapy, DeVIC dexamethasone, etoposide, ifosfamide, carboplatin, VIDP etoposide, ifosfamide, cisplatin, dexamethasone, VIDL etoposide, ifosfamide, dexamethasone, L-asparaginase, LVP L-asparaginase, vincristine, prednisoloen, GELOX gemcitabine, L-asparaginase, oxaliplatin, DICE-L dexamethasone, ifosfamide, cisplatinum, etoposide, L-asparaginase, SMILE dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide